Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)

Inclusion Criteria:

Provide signed and dated informed consent form.

* Aged 18 years or older.
* Have histologic evidence of malignant neoplasm that may have been obtained from the primary tumor or metastatic lymph node.
* Have a clinical decision made to receive external beam radiation therapy (EBRT) with curative intent, with or without concomitant chemotherapy.
* Have a good performance status (ECOG score 0-2) evaluated during screening (4 weeks prior to baseline imaging).
* Be willing to comply with all study procedures.
* Be willing to participate for the duration of the study.
* Have elevated dosimetric risk mainly characterized by any of the following criteria:

  * D30\>50Gy: 30% of the whole-mandible volume received a dose greater than 50 Gy
  * V44 ≥ 42%: at least 42% of the volume received a dose of 44 Gy or more or
  * V58 ≥ 25%: at least 25% of the volume received a dose of 58 Gy or more.

Exclusion Criteria:

Unable to tolerate DW-MRI or DCE-MRI;

* Having an estimated GFR \< 30 ml/min/1.73 m2;
* Contraindication to MRI (e.g., non-MRI compatible metallic implants)
* Pregnant females
* Unable or unwilling to give written, informed consent to undergo MRI imaging.
* Claustrophobia
* Unable to obtain imaging studies of adequate quality to assess imaging-based biomarkers.